Findings seen in mainly non-White race\/ethnicity patients hospitalized with confirmed SARS-CoV-2 infection<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, March 25, 2021 (HealthDay News) — For patients hospitalized with COVID-19, remdesivir is associated with a significant decrease in time to clinical improvement, but is not associated with a significant reduction in 28-day mortality, according to a study published online March 24 in JAMA Network Open<\/em>.<\/p>\n Brian T. Garibaldi, M.D., from the Johns Hopkins University School of Medicine in Baltimore, and colleagues conducted a retrospective comparative effectiveness research study from March 4 to Aug. 29, 2020, involving 2,483 individuals with confirmed severe acute respiratory syndrome coronavirus-2 infection in a five-hospital health system. Those receiving remdesivir were matched to infected individuals who did not receive remdesivir. Data were included for 342 individuals receiving remdesivir (80.7 percent self-identified as non-White race\/ethnicity), of whom 184 also received corticosteroids.<\/p>\n The researchers found that compared with matched controls, remdesivir recipients had a shorter time to clinical improvement (median, 5.0 versus 7.0 days; adjusted hazard ratio, 1.47). The 28-day mortality rate was 7.7 percent for remdesivir recipients compared with 14.0 percent for matched controls; in the time-to-death analysis, this difference was not statistically significant. There was no significant reduction in the risk for death at 28 days with the addition of corticosteroids to remdesivir.<\/p>\n “The inclusion of a larger proportion of patients from underrepresented minority groups provides much-needed evidence suggesting the effectiveness of remdesivir administration in these groups,” the authors write.<\/p>\n Two authors disclosed financial ties to the pharmaceutical and health care industries.<\/p>\n